{
  "extraction_metadata": {
    "timestamp": "2025-10-01T13:52:17.549089",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "temperature": 0.2
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "overall survival, progression-free survival, response (CR, PR, mRECIST), partial response, complete remission, tumour relapse, recurrence risk, intraoperative complications, mortality, morbidity, disease progression, time to progression of the tumor, time to deterioration, adverse events, neurotoxicity, EORTC QLQ-C30, EQ-5D-5L, Barcelona Clinic Liver Cancer (BCLC) Staging System, AFIP grading, WHO 3-member grading",
      "ChunksUsed": 20,
      "ContextTokens": 4698
    },
    "BE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "BE",
      "Outcomes": "partial response, survival, objective response, liver failure, pain, fever, serious complications, recurrence, adverse events (general), quality of life",
      "ChunksUsed": 20,
      "ContextTokens": 4689
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "overall survival, progression-free survival, partial response, complete remission, tumour response (mRECIST), tumour response (RECIST criteria), time to progression of the tumor, time to deterioration, intraoperative complications, mortality, morbidity, recurrence risk, adverse events, neurotoxicity, EORTC QLQ-C30, EQ-5D-5L",
      "ChunksUsed": 20,
      "ContextTokens": 4698
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "perioperative mortality, morbidity, leukaemia, postoperative softening, gallbladder abscess, complications (general), recurrence, long-term survival, local tumour control, quality of life",
      "ChunksUsed": 20,
      "ContextTokens": 3097
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "survival, prognosis (BCLC staging system), adverse events, long-term treatment-related complications",
      "ChunksUsed": 20,
      "ContextTokens": 4528
    },
    "EU": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EU",
      "Outcomes": "bleeding, tumour seeding, side-effects (biopsy), diagnosis (multiphasic CT and MRI, LI-RADS v2018), diagnosis (contrast-enhanced ultrasound), diagnosis (biopsy), diagnosis (immunohistochemistry markers), diagnosis (molecular genetic tests)",
      "ChunksUsed": 11,
      "ContextTokens": 2774
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "overall survival, progression-free survival, time-to-progression, objective response rate (modified RECIST criteria), objective response rate (RECIST criteria), adverse events, diarrhoea, fatigue, nausea, neutropenia, anaemia, headache, rash, liver and biliary damages, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L, SF-36, visual analogue scale",
      "ChunksUsed": 20,
      "ContextTokens": 5940
    },
    "IT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "IT",
      "Outcomes": "",
      "Error": "Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4.1 in organization org-qjlBCLCPywLruyzWD3MengrF on tokens per min (TPM): Limit 30000, Used 24390, Requested 5941. Please try again in 662ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens', 'param': None, 'code': 'rate_limit_exceeded'}}",
      "ChunksUsed": 20,
      "ContextTokens": 4764
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, progression-free survivorship, response rate, adverse events, adverse events (Grade â‰¥ 3), serious adverse events, quality of life, overall quality of life (measured with a validated and reliable instrument), Functional Assessment of Cancer Therapy (FACT-G), Functional Assessment of Cancer Therapy - Hepatobiliary (FACT-Hep), EQ-5D, EQ-VAS, distress, physical complaints, psychological complaints, psychosocial complaints, early detection of local recurrence, early detection of de novo tumor, alpha-fetoprotein (AFP) monitoring, pulmonary metastasis, lung metastasis",
      "ChunksUsed": 20,
      "ContextTokens": 4673
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "overall survival, response rates (RECIST criteria), response rates (mRECIST), response rates (RECIS systems), perioperative mortality, adverse events (general), time to progression, completeness of ablation (multiphase computed tomography with contrast), completeness of ablation (magnetic resonance imaging with contrast), effectiveness of ablation (magnetic resonance imaging), effectiveness of ablation (multiphase computed tomography), effectiveness of ablation (ultrasonography not appropriate), disease progression, bridging therapy (prevention of progression), histological and prognostic parameters (microscopic detection), immunohistochemical confirmation of hepatocytic origin, genetic diagnosis (identification of subtypes), undesirable effects (general), adverse effects on development of hepatocellular carcinoma, quality of life (no specific instrument named)",
      "ChunksUsed": 15,
      "ContextTokens": 3401
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "survival, health-related quality of life, EORTC QLQ-C30, FACT-G, EORTC QLQ-HCC18, FACT-Hep, response rates (RECIST criteria), response rates (mRECIST criteria), overall response rate (mRECIST), tumour viability (mRECIST), nutritional status, concentration difficulties, emotional impact, physical needs, psychological needs, social needs, existential needs, adverse events",
      "ChunksUsed": 20,
      "ContextTokens": 3362
    }
  }
}